Post-Conference Perspectives: Recent Advances in the Management of Chronic GvHD - Episode 3

Defining and Managing Steroid Refractory Chronic GvHD

July 26, 2023

Preet M. Chaudhary, MD, PhD, Noah Merin, MD, PhD

Dr. Merin defines steroid refractory chronic GvHD, explains how to determine when patients become steroid-refractory and discusses treatment approach for this population.

EP. 1: The Chronic GvHD Landscape: Risk Factors and Diagnosis

EP. 2: First-line Treatment for Patients with Chronic GvHD

Now Viewing

EP. 3: Defining and Managing Steroid Refractory Chronic GvHD

EP. 4: Role of Ruxolitinib in Steroid-Refractory Chronic GvHD

EP. 5: Understanding Mechanisms of Action: Ruxolitinib, Ibrutinib, and Belumosudil

EP. 6: Key Efficacy Data of Ibrutinib and Belumosudil in Steroid-Refractory Chronic GvHD Patients

EP. 7: Real World Data on the Use of Ruxolitinib and Treatment Selection in chronic GvHD

EP. 8: Future Directions in Chronic GvHD